|
|
|
| home > white papers > Clinical Trials in Russia Orange Paper: Summary of Year 2013 - Synergy Research Group |
|
|
 WHITE PAPERS |
|
Synergy Research Group
|
|
Clinical Trials in Russia Orange Paper: Summary of Year 2013
|
|
Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4.
Low cost: Average per patient cost is 60% to 70% below US and European
prices due to the low cost of Investigators and the high concentration
of patients in therapeutically aligned medical centers
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
New research calls for pathology services to be better funded and prioritised
More info >> |
|
 |
White Papers |
 |
|
Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections
IBT Bioservices
Introduction
Staphylococcus aureus (SA) is a ubiquitous, formidable
Gram-positive pathogen associated with skin and soft tissue, as well as
lifethreatening systemic infections. SA is a leading cause of hospital- and
community-associated infections worldwide, affecting humans and animals. The
wide range of pathologies reflects the diverse abilities of this microbe to
escape the innate and adaptive immune response using virulence factors. Since
its first emergence in the 1960s methicillin-resistant SA (MRSA) has become
endemic in hospitals and healthcare settings worldwide. In the 1990s, community
associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a
major global challenge.
More info >> |
|
 |
Industry Events |
 |
6th Annual Cancer Vaccines Conference
27-28 September 2017, Copthorne Tara Hotel, London UK
Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >> |
|
|
|
